Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor

BACKGROUND: A common genetic mutation that causes Parkinson's disease (PD) is the G2019S LRRK2 mutation. A precision medicine approach that selectively blocks only excess kinase activity of the mutant allele could yield a safe and effective treatment for G2019S LRRK2 PD. OBJECTIVE: To determine...

Descripción completa

Detalles Bibliográficos
Autores principales: Bright, Jessica M., Carlisle, Holly J., Toda, Alyssa M. A., Murphy, Molly, Molitor, Tyler P., Wren, Paul, Andruska, Kristin M., Liu, Enchi, Barlow, Carrolee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Regular Issue Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248170/
https://www.ncbi.nlm.nih.gov/pubmed/33836114
http://dx.doi.org/10.1002/mds.28490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248170/
https://www.ncbi.nlm.nih.gov/pubmed/33836114
http://dx.doi.org/10.1002/mds.28490

Ejemplares similares